Compare MS & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MS | AZN |
|---|---|---|
| Founded | 1924 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.4B | 276.3B |
| IPO Year | N/A | 1993 |
| Metric | MS | AZN |
|---|---|---|
| Price | $174.67 | $89.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 2 |
| Target Price | ★ $167.38 | N/A |
| AVG Volume (30 Days) | ★ 5.5M | 5.5M |
| Earning Date | 01-15-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.29% | 1.70% |
| EPS Growth | ★ 48.48 | 45.02 |
| EPS | ★ 9.75 | 6.02 |
| Revenue | ★ $68,532,000,000.00 | $58,127,000,000.00 |
| Revenue This Year | $17.60 | $11.33 |
| Revenue Next Year | $5.64 | $6.08 |
| P/E Ratio | $17.94 | ★ $14.97 |
| Revenue Growth | ★ 17.59 | 13.52 |
| 52 Week Low | $94.33 | $61.24 |
| 52 Week High | $176.00 | $94.02 |
| Indicator | MS | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 67.94 | 56.74 |
| Support Level | $168.10 | $90.14 |
| Resistance Level | $170.27 | $91.28 |
| Average True Range (ATR) | 4.14 | 1.34 |
| MACD | 1.06 | -0.22 |
| Stochastic Oscillator | 94.58 | 29.73 |
Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 80,000 employees as of year-end 2024. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $7.9 trillion in client assets at the end of its most recent fiscal year. After reincorporation as a bank holding company in the wake of the great financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with nearly $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.